Your session is about to expire
← Back to Search
Transitional Care Model for Heart Failure (TCM2020 Trial)
N/A
Waitlist Available
Led By Randall S Brown, PhD
Research Sponsored by Mathematica Policy Research, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Admitted from home with Pneumonia OR with a history of HF or COPD with symptoms of HF or COPD exacerbation or whose symptoms suggest a new HF or COPD diagnosis
Age 65 years and older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
TCM2020 Trial Summary
This trial will study the effects of the transitional care model on hospital admissions and patients' experience during the year following the patient's qualifying discharge.
Who is the study for?
This trial is for adults aged 65 and older who have been hospitalized with heart failure, COPD, or pneumonia. Participants must live in the service area, be reachable by phone after discharge, and able to answer questions. They can't be in long-term care or other trials, enrolled in certain Medicare programs, have untreated psychiatric conditions or be undergoing cancer treatment.Check my eligibility
What is being tested?
The study compares a Transitional Care Model (TCM) against usual care to see if TCM reduces hospital readmissions and improves patient experience post-discharge. It's a randomized controlled trial conducted across three U.S. health systems involving seven hospitals.See study design
What are the potential side effects?
Since this trial tests a care model rather than a drug, there are no direct side effects like those associated with medications. However, changes in care management could impact patient satisfaction and healthcare utilization.
TCM2020 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I was admitted from home with pneumonia or have a history of heart failure (HF) or chronic obstructive pulmonary disease (COPD) with worsening symptoms.
Select...
I am 65 years old or older.
TCM2020 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Costs
Number of hospital admissions
Secondary outcome measures
30-day readmission
Edmonton Symptom Assessment Scale
Mortality
+3 moreOther outcome measures
Home Health
Skilled nursing facility days
hospice
+1 moreTCM2020 Trial Design
2Treatment groups
Experimental Treatment
Group I: Treatment groupExperimental Treatment1 Intervention
The treatment group receives the TCM intervention while in the hospital and during the first 90 days after returning to the community.
Group II: Control groupExperimental Treatment1 Intervention
The control group receives usual discharge planning and post-discharge care.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Usual care
2011
Completed Phase 4
~23770
Find a Location
Who is running the clinical trial?
Mathematica Policy Research, Inc.Lead Sponsor
57 Previous Clinical Trials
6,117,531 Total Patients Enrolled
University of PennsylvaniaOTHER
2,000 Previous Clinical Trials
42,879,126 Total Patients Enrolled
Arnold VenturesUNKNOWN
2 Previous Clinical Trials
1,132 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I can be reached by phone after leaving the hospital.I was admitted from home with pneumonia or have a history of heart failure (HF) or chronic obstructive pulmonary disease (COPD) with worsening symptoms.I do not have untreated mental health conditions.I can answer questions, regardless of my primary language.You are currently in a hospice or end-stage renal disease program through Medicare.I am 65 years old or older.I am currently receiving treatment for cancer.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment group
- Group 2: Control group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any available slots for participants in this research study?
"Yes, this is an ongoing clinical trial that has been seeking patients since July 7th 2020. The study's page on the website clinicaltrials.gov was last updated on August 31st 2020."
Answered by AI
What is the primary goal of this clinical trial?
"The primary metric used to gauge the success of this 12-month clinical trial is "Costs." Other important, yet secondary outcomes include the "Edmonton Symptom Assessment Scale" measuring a patient's post-hospital symptoms (on a scale from 0-100), number of emergency department visits after being discharged, and mortality rates."
Answered by AI
How many research subjects are enrolled in this experiment?
"That is correct, the clinicaltrials.gov website has information indicating that this study is still actively looking for patients. The trial was originally posted on 7/7/2020 and the most recent update was on 8/31/2020. They are hoping to enroll 1600 people at 1 locations."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger